Wipro to buy EVA and Good Home for ₹256 cr in 2026

Deal snapshot: what has been announced

Wipro Enterprises Private Limited has signed definitive agreements to acquire TTK Healthcare Ltd’s consumer brands EVA and Good Home, along with related assets, for ₹256 crore plus applicable GST. The agreements were executed on July 23, 2026, after TTK Healthcare’s board approved the transaction. The deal is expected to be completed by September 30, 2026, subject to fulfilment of customary conditions precedent. TTK Healthcare has disclosed that the net book value of the related assets was ₹0.70 crore as of June 30, 2026. The two brands together generated revenue of about ₹148 crore in FY26 and accounted for around 17% of TTK Healthcare’s turnover for the year.

Who is buying and who is selling

TTK Healthcare Limited is the seller in this transaction, while Wipro Enterprises Private Limited is the buyer. As per the disclosures, Wipro Enterprises is not part of TTK Healthcare’s promoter group. TTK Healthcare has also stated that the sale does not fall under related-party transactions. The transaction is being undertaken outside a scheme of arrangement, and it is not classified as a slump sale. These details matter for investors because they set expectations on regulatory process, governance checks, and how the transaction may be reported in statutory filings.

Brands in focus: EVA and Good Home portfolios

Good Home is positioned as TTK Healthcare’s home-care brand. Its product range includes air care, odour removers, scrubbers, and drain cleaners, which place it in everyday household usage categories. EVA is a personal-care brand with offerings such as deodorants, body sprays, no-gas perfumes, underarm roll-ons, and talcum powders. Together, the two brands give exposure to home hygiene and personal grooming segments where frequency of purchase is typically higher than in many healthcare categories. The acquisition is intended to strengthen Wipro’s presence in home and personal care segments, based on the stated rationale around portfolio expansion.

Financial details: consideration, revenue base, and asset value

The headline consideration for the deal is ₹256 crore, plus applicable GST. The disclosed FY26 revenue of the two brands is approximately ₹148 crore. TTK Healthcare has described this revenue as around 17% of its total turnover in FY26, and a separate disclosure pegs FY26 turnover at ₹857.28 crore. The net book value of the related assets, at ₹0.70 crore as of June 30, 2026, indicates that the deal value is largely driven by brand and business value rather than balance-sheet asset backing. Such differences between consideration and net book value are common in brand-heavy consumer businesses where distribution, brand recall, and product positioning carry significant value.

Timeline: board approval to expected closing

The sequence disclosed by the company is clear. TTK Healthcare’s board approved the transaction on July 23, 2026. Definitive agreements were signed the same day. The expected closing date is September 30, 2026, subject to completion of the conditions precedent. This sets a defined window for completion and for any remaining approvals, documentation, or customary transaction steps. While the specifics of conditions precedent are not detailed in the available information, the company has indicated that the closing is contingent on fulfilling those conditions.

Key numbers at a glance

What it means for TTK Healthcare

For TTK Healthcare, EVA and Good Home together represent a meaningful slice of the company’s turnover at about 17% in FY26. Divesting these brands therefore reshapes the mix of the company’s consumer-facing portfolio. The company has positioned the move as a strategic divestment, and the disclosures highlight the expected timing and consideration rather than a broader reorganisation. Since the consideration is ₹256 crore plus GST, the transaction could also affect reported cash flows once completed, although the exact accounting treatment and post-transaction deployment of proceeds are not described in the provided details.

What it means for Wipro Enterprises and its consumer-care strategy

On the buyer side, Wipro Enterprises is using the acquisition to strengthen its presence in home and personal care. The disclosed FY26 revenue base of ₹148 crore provides a scale reference for the assets being acquired. Another disclosure describes this as Wipro Consumer Care’s 17th acquisition, indicating that inorganic expansion has been part of the strategy. With product lines spanning air care, home cleaning adjuncts, and personal fragrances and deodorants, the acquisition adds established brand assets rather than building entirely new labels. The deal structure also avoids related-party complications based on the filing information.

Market impact: what investors can track next

The key near-term market variable is completion by September 30, 2026, given the transaction is subject to customary conditions precedent. Investors tracking TTK Healthcare will likely focus on how the company reports the divestment of brands that contributed ~₹148 crore in FY26 revenue and ~17% of turnover. The difference between the ₹256 crore consideration and the ₹0.70 crore net book value of related assets underscores that the transaction is driven by intangible value, which can affect how stakeholders interpret the deal’s valuation logic. For the broader FMCG and consumer-care space, the deal is another example of portfolio consolidation through brand acquisitions in everyday-use categories.

Analysis: why the transaction stands out

Two data points stand out in the disclosures. First, the revenue base of ₹148 crore for EVA and Good Home provides a measurable yardstick for the acquisition. Second, the disclosed net book value of assets at ₹0.70 crore highlights the gap between hard assets and brand-led valuation, which is typical in branded consumer segments. The transaction’s classification as non-related-party, not a slump sale, and outside a scheme of arrangement points to a relatively straightforward structure from a compliance and governance standpoint. The defined closing date, September 30, 2026, gives a concrete checkpoint for the next set of updates through exchange filings.

Conclusion

TTK Healthcare has agreed to sell its EVA and Good Home brands and related assets to Wipro Enterprises for ₹256 crore plus GST, with agreements signed and board approval on July 23, 2026. The transaction is expected to close by September 30, 2026, subject to conditions precedent. The divested brands generated about ₹148 crore in FY26 revenue and represented around 17% of TTK Healthcare’s turnover, making this a significant portfolio change. The next milestone to watch is completion of the transaction by the stated date and the subsequent disclosures around the final closing.